Pharmacoeconomic analysis of anti-VEGF therapy for age-related macular degeneration
Diabetes mellitus (DM) is a widespread, severe disease that has outpaced many infectious and non-infectious diseases in terms of both incidence increases and economic burden in most developed countries. In addition to the direct threat to the health and well-being of patients, DM is associated with...
Saved in:
Main Authors: | A. E. Cheberda (Author), D. Yu. Belousov (Author), M. M. Shishkin (Author) |
---|---|
Format: | Book |
Published: |
Izdatelstvo OKI,
2018-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pharmacoeconomic analysis of ranibizumab and aflibercept for treatment of diabetic macular edema
by: A. E. Cheberda, et al.
Published: (2018) -
Pharmacokinetics of Intravitreal Anti-VEGF Drugs in Age-Related Macular Degeneration
by: Laura García-Quintanilla, et al.
Published: (2019) -
Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review
by: Yang S, et al.
Published: (2016) -
Current and Future Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration
by: Kaiser SM, et al.
Published: (2021) -
Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: a systematic review and meta-analysis
by: Ba J, et al.
Published: (2015)